Clinical Pathways
Clinical Pathways
Moderate or high suspicion
Moderate or high suspicion

Moderate or high suspicion

View The Full Pathway

Action

Initiate STI diagnostic testing

Decision

Symptoms and physical examination findings

Background

image

Patients may present to urgent care seeking testing for STIs following a sexual encounter or other potential exposure, prior to the emergence of any signs or symptoms. While empiric treatment or PEP for STIs should not be delayed by confirmatory testing, patients should be counseled that the accuracy of test results may be impacted by the length of time that has passed since exposure, as well as other factors such as the type of infectious agent, the site(s) of exposure, and the underlying health of the patient. 

‣
References
  1. Are sex toys safe? National Health Service England. Updated January 5, 2023. Accessed February 10, 2023. (UK National Health Service informational webpage)
  2. Kessler R, Hinkle BT, Moyers A, et al. Adolescent sexual health: identity, risk, and screening for sexually transmitted infections. Prim Care. 2020;47(2):367-382. (Review) DOI: 10.1016/j.pop.2020.02.012
  3. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40(3):187-193. (Review)
  4. Silverberg B, Moyers A, Hinkle BT, et al. 2021 CDC update: treatment and complications of sexually transmitted infections (STIs). Venereology. 2022;1(1):23-46. (Review of CDC recommendations) DOI: 10.3390/venereology1010004
  5. New data suggest STDs continued to increase during first year of the COVID-19 pandemic. Centers for Disease Control and Prevention. News release. April 22, 2022. Accessed February 10, 2023. (Press release)
  6. 2017 STD surveillance report. Centers for Disease Control and Prevention. Last reviewed September 25, 2018. Accessed February 10, 2023. (CDC guidelines)
  7. Torrone E, Papp J, Weinstock H. Prevalence of Chlamydia trachomatis genital infection among persons aged 14-39 years--United States, 2007-2012. MMWR Morb Mortal Wkly Rep. 2014;63(38):834-838. (Expert guideline/systematic review)
  8. Corsaro D, Venditti D. Emerging chlamydial infections. Crit Rev Microbiol.2004;30(2):75-106. (Review)
  9. Newman L, Rowley J, Vander Hoorn S, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One. 2015;10(12):e0143304. (Review)
  10. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. (Expert guidelines/systematic review) DOI: 10.15585/mmwr.rr7004a1
  11. Fethers KA, Fairley CK, Morton A, et al. Early sexual experiences and risk factors for bacterial vaginosis. J Infect Dis. 2009;200(11):1662-1670. (Cross-sectional study; 540 patients)
  12. Centers for Disease Control and Prevention, Division of STD Prevention. Sexually Transmitted Disease Surveillance 2017. 2018. Accessed February 10, 2023. (CDC report)
  13. Peeling RW, Hook EW, 3rd. The pathogenesis of syphilis: the Great Mimicker, revisited. J Pathol. 2006;208(2):224-232. (Review)
  14. Liu LL, Zheng WH, Tong ML, et al. Ischemic stroke as a primary symptom of neurosyphilis among HIV-negative emergency patients. J Neurol Sci. 2012;317(1-2):35-39. (Retrospective review; 149 patients with neurosyphilis)
  15. Esber A, Vicetti Miguel RD, Cherpes TL, et al. Risk of bacterial vaginosis among women with herpes simplex virus type 2 infection: a systematic review and meta-analysis. J Infect Dis. 2015;212(1):8-17. (Meta-analysis/systematic review; 17 studies)
  16. Myer L, Denny L, Telerant R, et al. Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. J Infect Dis. 2005;192(8):1372-1380. (Case control study; 5110 patients)
  17. Balkus JE, Richardson BA, Rabe LK, et al. Bacterial vaginosis and the risk of trichomonas vaginalis acquisition among HIV-1-negative women. Sex Transm Dis. 2014;41(2):123-128.(Randomized controlled trial; 2920 patients)
  18. O'Farrell N. Donovanosis. Sex Transm Infect. 2002;78(6):452-457. (Review)
  19. Mabey D, Peeling RW. Lymphogranuloma venereum. Sex Transm Infect. 2002;78(2):90-92. (Review)
  20. Ceovic R, Gulin SJ. Lymphogranuloma venereum: diagnostic and treatment challenges. Infect Drug Resist. 2015;8:39-47. (Review)
  21. Sethi S, Singh G, Samanta P, et al. Mycoplasma genitalium: an emerging sexually transmitted pathogen. Indian J Med Res. 2012;136(6):942-955. (Review)
  22. Alfarraj DA, Somily AM. Isolation of Mycoplasma genitalium from endocervical swabs of infertile women. Saudi Med J. 2017;38(5):549-552. (Prospective case control study; 200 patients)
  23. Bradley H, Markowitz LE, Gibson T, et al. Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010. J Infect Dis. 2014;209(3):325-333. (Review)
  24. Bernstein DI, Bellamy AR, Hook EW, 3rd, et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis. 2013;56(3):344-351. (Prospective cohort study; 3438 patients)
  25. HPV infection. Centers for Disease Control and Prevention. Last reviewed July 23, 2021. Accessed February 10, 2023. (CDC website)
  26. 1 in 5 people in the U.S. have a sexually transmitted infection. Centers for Disease Control and Prevention. News release. January 25, 2021. Accessed February 10, 2023. (Press release)
  27. Rathod SD, Krupp K, Klausner JD, et al. Bacterial vaginosis and risk for Trichomonas vaginalis infection: a longitudinal analysis. Sex Transm Dis. 2011;38(9):882-886.(Prospective cohort study; 853 patients)
  28. Kandamuthan S, Thambi R, Yeshodharan J. Trichomoniasis: is it always sexually transmitted? Indian J Sex Transm Dis AIDS. 2014;35(2):166-167. (Case report)
  29. A guide to taking a sexual history. Centers for Disease Control and Prevention. Last reviewed January 14, 2022. Accessed February 10, 2023. (CDC clinician guidance)
  30. Choudhry S, Ramachandran VG, Das S, et al. Characterization of patients with multiple sexually transmitted infections: A hospital-based survey. Indian J Sex Transm Dis AIDS. 2010;31(2):87-91. (Retrospective; 102 patients)
  31. Ward H, Rönn M. Contribution of sexually transmitted infections to the sexual transmission of HIV. Curr Opin HIV AIDS. 2010;5(4):305-310. (Review)
  32. Brown J, Fleming R, Aristzabel J, et al. Does pelvic exam in the emergency department add useful information? West J Emerg Med. 2011;12(2):208-212. (Prospective study; 183 patients)
  33. Tomas ME, Getman D, Donskey CJ, et al. Overdiagnosis of urinary tract infection and underdiagnosis of sexually transmitted infection in adult women presenting to an emergency department. J Clin Microbiol. 2015;53(8):2686-2692. (Cohort study; 264 women)
  34. Geisler WM, Chow JM, Schachter J, et al. Pelvic examination findings and Chlamydia trachomatis infection in asymptomatic young women screened with a nucleic acid amplification test. Sex Transm Dis. 2007;34(6):335-338. (Retrospective study; 577 patients)
  35. Sherrard J, Barlow D. Gonorrhoea in men: clinical and diagnostic aspects. Genitourin Med. 1996;72(6):422-426. (Retrospective study; 1382 patients)
  36. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007;34(11):864-869. (Prospective study; 3739 patients)
  37. Richens J. Donovanosis (granuloma inguinale). Sex Transm Infect. 2006;82 Suppl 4(Suppl 4):iv21-22. (Review)
  38. Roest RW, van der Meijden WI. European guideline for the management of tropical genito-ulcerative diseases. Int J STD AIDS. 2001;12 Suppl 3:78-83. (Practice guidelines)
  39. White JA. Manifestations and management of lymphogranuloma venereum. Curr Opin Infect Dis. 2009;22(1):57-66. (Review)
  40. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296(8):964-973. (Cross-sectional review)
  41. Lautenschlager S, Eichmann A. Urethritis: an underestimated clinical variant of genital herpes in men? J Am Acad Dermatol. 2002;46(2):307-308. (Review)
  42. Mertz GJ. Asymptomatic shedding of herpes simplex virus 1 and 2: implications for prevention of transmission. J Infect Dis. 2008;198(8):1098-1100. (Review)
  43. Merin A, Pachankis JE. The psychological impact of genital herpes stigma. J Health Psychol. 2011;16(1):80-90. (Review)
  44. Ault KA. Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol. 2006;2006 Suppl:40470. (Review)
  45. Schwebke JR, Burgess D. Trichomoniasis. Clin Microbiol Rev. 2004;17(4):794-803, table of contents. (Review)
  46. Adamson PC, Loeffelholz MJ, Klausner JD. Point-of-care testing for sexually transmitted infections: a review of recent developments. Arch Pathol Lab Med. 2020;144(11):1344-1351. (Review) DOI: 10.5858/arpa.2020-0118-RA
  47. FDA allows for first point-of-care chlamydia and gonorrhea test to be used in more near-patient care settings. News release. US Food and Drug Administration. March 30, 2021. Accessed February 10, 2023. (Press release)
  48. Landers DV, Wiesenfeld HC, Heine RP, et al. Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol. 2004;190(4):1004-1010.(Prospective study; 598 patients)
  49. Centers for Disease Control and Prevention. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae--2014. MMWR Recomm Rep. 2014;63(Rr-02):1-19. (Expert guidelines/systematic review)
  50. Pickett ML, Visotcky A, Brazauskas R, et al. Can a clean catch urine sample be used to diagnose chlamydia and gonorrhea in adolescent females? J Adolesc Health. 2021;69(4):574-578. (Prospective cohort study; 323 patients)
  51. Haugland S, Thune T, Fosse B, et al. Comparing urine samples and cervical swabs for Chlamydia testing in a female population by means of Strand Displacement Assay (SDA). BMC Womens Health. 2010;10:9. (Comparative study; 603 patients)
  52. Plavchan J. Testing options for the detection of gonorrhea and Chlamydia. Am Fam Physician. 2013;88(5):290-291. (Letter to the editor)
  53. Skidmore S, Horner P, Herring A, et al. Vulvovaginal-swab or first-catch urine specimen to detect Chlamydia trachomatis in women in a community setting? J Clin Microbiol. 2006;44(12):4389-4394. (Retrospective study; 2745 specimens)
  54. Hobbs MM, van der Pol B, Totten P, et al. From the NIH: proceedings of a workshop on the importance of self-obtained vaginal specimens for detection of sexually transmitted infections. Sex Transm Dis. 2008;35(1):8-13. (Expert guidelines/workshop review)
  55. Cook RL, Hutchison SL, Østergaard L, et al. Systematic review: noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med. 2005;142(11):914-925. (Systematic review; 29 studies)
  56. Renault CA, Hall C, Kent CK, et al. Use of NAATs for STD diagnosis of GC and CT in non-FDA -cleared anatomic specimens. MLO Med Lab Obs. 2006;38(7):10, 12-16, 21-12.(Guidelines and review)
  57. van der Helm JJ, Hoebe CJ, van Rooijen MS, et al. High performance and acceptability of self-collected rectal swabs for diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men and women. Sex Transm Dis. 2009;36(8):493-497. (Cross-sectional study; 2394 patients)
  58. Kowalski RP, Karenchak LM, Raju LV, et al. The verification of nucleic acid amplification testing (Gen-Probe Aptima Assay) for chlamydia trachomatis from ocular samples. Ophthalmology. 2015;122(2):244-247. (Retrospective laboratory verification study; 25 specimens)
  59. Stewart CM, Schoeman SA, Booth RA, et al. Assessment of self taken swabs versus clinician taken swab cultures for diagnosing gonorrhoea in women: single centre, diagnostic accuracy study. BMJ. 2012;345:e8107. (Prospective study; 3850 patients)
  60. Soreng K, Levy R, Fakile Y. Serologic testing for syphilis: benefits and challenges of a reverse algorithm. Clin Microbiol Newsl. 2014;36(24):195-202. (Review)
  61. Association of Public Health Laboratories. Laboratory diagnostic testing for Treponema pallidum: expert consultation meeting summary report. 2009. Accessed February 10, 2023. (Expert guidelines)
  62. Ghanem KG, Ram S, Rice PA. The modern epidemic of syphilis. N Engl J Med. 2020;382(9):845-854. (Review) DOI: 10.1056/NEJMra1901593
  63. Centers for Disease Control and Prevention. Discordant results from reverse sequence syphilis screening--five laboratories, United States, 2006-2010. MMWR Morb Mortal Wkly Rep. 2011;60(5):133-137. (Data analysis; 5 laboratories)
  64. Noy M, Rayment M, Sullivan A, et al. The utility of cerebrospinal fluid analysis in the investigation and treatment of neurosyphilis. Sex Transm Infect. 2014;90(6):451. (Expert guidelines)
  65. Wølner-Hanssen P, Krieger JN, Stevens CE, et al. Clinical manifestations of vaginal trichomoniasis. JAMA. 1989;261(4):571-576. (Prospective study; 779 patients)
  66. Eschenbach DA, Hillier S, Critchlow C, et al. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol. 1988;158(4):819-828. (Prospective study; 640 patients)
  67. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74(1):14-22. (Prospective study; 397 patients)
  68. Van der Bij AK, Spaargaren J, Morré SA, et al. Diagnostic and clinical implications of anorectal lymphogranuloma venereum in men who have sex with men: a retrospective case-control study. Clin Infect Dis. 2006;42(2):186-194. (Retrospective; 87 patients)
  69. Corey L, Huang ML, Selke S, et al. Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay. J Med Virol. 2005;76(3):350-355.(Prospective; 3131 specimens)
  70. Roth AM, Williams JA, Ly R, et al. Changing sexually transmitted infection screening protocol will result in improved case finding for trichomonas vaginalis among high-risk female populations. Sex Transm Dis. 2011;38(5):398-400. (Prospective studies; 222 patients and 471 patients)
  71. Schwebke JR, Hobbs MM, Taylor SN, et al. Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial. J Clin Microbiol. 2011;49(12):4106-4111. (Prospective multicenter study; 1025 patients)
  72. Cristillo AD, Bristow CC, Peeling R, et al. Point-of-care sexually transmitted infection diagnostics: proceedings of the STAR sexually transmitted infection-clinical trial group programmatic meeting. Sex Transm Dis. 2017;44(4):211-218. (Review)
  73. Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis. 2002;29(9):497-502. (Meta-analysis; 12 clinical trials)
  74. Dombrowski JC, Wierzbicki MR, Newman LM, et al. Doxycycline versus azithromycin for the treatment of rectal chlamydia in men who have sex with men: a randomized controlled trial. Clin Infect Dis. 2021;73(5):824-831. (Randomized controlled trial; 177 patients)
  75. STI Treatment Guidelines, 2021: Chlamydial infection among adolescents and adults. Centers for Disease Control and Prevention. Last reviewed July 22, 2021. Accessed February 10, 2023. (CDC guidelines)
  76. Workowski KA, Berman SM, Douglas JM, Jr. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med. 2008;148(8):606-613. (Review)
  77. The American College of Obstetricians and Gynecologists. Management of genital herpes in pregnancy: ACOG Practice Bulletin, Number 220. Obstet Gynecol.2020;135(5):e193-e202. (Practice guidelines) DOI: 10.1097/AOG.0000000000003840
  78. Yokoi S, Deguchi T, Ozawa T, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis. 2007;13(8):1275-1277. (Prospective study; 4 patients)
  79. Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis. 2014;59(8):1083-1091. (Randomized controlled trial; 401 patients)
  80. STI Treatment Guidelines, 2021: Gonococcal infections among adolescents and adults. Centers for Disease Control and Prevention. Last reviewed September 21, 2022. Accessed February 10, 2023. (CDC guidelines)
  81. Syphilis – CDC detailed fact sheet. Centers for Disease Control and Prevention. Last reviewed April 12, 2022. Accessed February 10, 2023. (CDC fact sheet)
  82. Clement ME, Okeke NL, Hicks CB. Treatment of syphilis: a systematic review. JAMA. 2014;312(18):1905-1917. (Review)
  83. Butler T. The Jarisch-Herxheimer reaction after antibiotic treatment of spirochetal infections: a review of recent cases and our understanding of pathogenesis. Am J Trop Med Hyg. 2017;96(1):46-52. (Review)
  84. Belum GR, Belum VR, Chaitanya Arudra SK, et al. The Jarisch-Herxheimer reaction: revisited. Travel Med Infect Dis. 2013;11(4):231-237. (Review)
  85. Caro-Patón T, Carvajal A, Martin de Diego I, et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol. 1997;44(2):179-182. (Meta-analysis of 1 case-control and 4 cohort studies)
  86. Hanson JM, McGregor JA, Hillier SL, et al. Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs. oral therapy. J Reprod Med. 2000;45(11):889-896.(Randomized controlled trial, comparative study; 112 patients)
  87. Homayouni A, Bastani P, Ziyadi S, et al. Effects of probiotics on the recurrence of bacterial vaginosis: a review. J Low Genit Tract Dis. 2014;18(1):79-86. (Systematic review)
  88. Chosidow O, Drouault Y, Leconte-Veyriac F, et al. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br J Dermatol. 2001;144(4):818-824. (Randomized controlled study; 204 patients)
  89. Vodstrcil LA, Plummer EL, Doyle M, et al. Treating male partners of women with bacterial vaginosis (StepUp): a protocol for a randomised controlled trial to assess the clinical effectiveness of male partner treatment for reducing the risk of BV recurrence. BMC Infect Dis. 2020;20(1):834. (Randomized controlled trial; 342 couples) DOI: 10.1186/s12879-020-05563-w
  90. Johnston C, Saracino M, Kuntz S, et al. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet. 2012;379(9816):641-647. (3 complementary crossover studies; 113 patients)
  91. Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med. 2008;168(11):1137-1144. (Review)
  92. World Health Organization. Recommendations for treatment of genital herpes simplex virus. In: WHO Guidelines for the Treatment of Genital Herpes Simplex Virus. 2016; chap 4. Accessed February 10. 2023. (Guidelines)
  93. Lipke MM. An armamentarium of wart treatments. Clin Med Res. 2006;4(4):273-293.(Review)
  94. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2016;65(49):1405-1408.(Guidelines/systematic review)
  95. STI Treatment Guidelines, 2021: Trichomoniasis. Centers for Disease Control and Prevention. Last reviewed September 21, 2022. Accessed February 10, 2023. (CDC guidelines)
  96. Wyrick PB. Chlamydia trachomatis persistence in vitro: an overview. J Infect Dis. 2010;201 Suppl 2(Suppl 2):S88-S95. (Review)
  97. Majeroni BA, Ukkadam S. Screening and treatment for sexually transmitted infections in pregnancy. Am Fam Physician. 2007;76(2):265-270. (Review)
  98. Liu B, Roberts CL, Clarke M, et al. Chlamydia and gonorrhoea infections and the risk of adverse obstetric outcomes: a retrospective cohort study. Sex Transm Infect.2013;89(8):672-678. (Retrospective cohort study; 354,217 patients)
  99. Newman L, Kamb M, Hawkes S, et al. Global estimates of syphilis in pregnancy and associated adverse outcomes: analysis of multinational antenatal surveillance data. PLoS Med. 2013;10(2):e1001396. (Review)
  100. Walker GJ. Antibiotics for syphilis diagnosed during pregnancy. Cochrane Database Syst Rev. 2001;2001(3):CD001143. (Cochrane review; 0 studies meeting criteria)
  101. McGregor JA, French JI. Bacterial vaginosis in pregnancy. Obstet Gynecol Surv. 2000;55(5 Suppl 1):S1-19. (Review)
  102. Watts DH, Brown ZA, Money D, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. Am J Obstet Gynecol. 2003;188(3):836-843. (Randomized controlled trial; 162 patients)
  103. Castellsagué X, Drudis T, Cañadas MP, et al. Human papillomavirus (HPV) infection in pregnant women and mother-to-child transmission of genital HPV genotypes: a prospective study in Spain. BMC Infect Dis. 2009;9:74. (Prospective cohort study; 143 patients)
  104. STI Treatment Guidelines, 2021: Reporting and confidentiality. Centers for Disease Control and Prevention. Last reviewed July 22, 2021. Accessed February 10, 2023. (Guideline)
  105. Cotch MF, Pastorek JG, 2nd, Nugent RP, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis. 1997;24(6):353-360. (Prospective cohort study; 3816 patients)
  106. Gülmezoglu AM. Interventions for trichomoniasis in pregnancy. Cochrane Database Syst Rev. 2002(3):CD000220. (Cochrane review; 2 trials, 842 women)
  107. Joesoef MR, Weinstock HS, Kent CK, et al. Sex and age correlates of Chlamydia prevalence in adolescents and adults entering correctional facilities, 2005: implications for screening policy. Sex Transm Dis. 2009;36(2 Suppl):S67-S71. (Cross-sectional analysis; 150,166 patients)
  108. Strick LB, Budak JZ. HIV and corrections. National HIV Curriculum. Updated August 26, 2020. Accessed February 10, 2023. (Review)
  109. European Centre for Disease Prevention and Control. Response plan to control and manage the threat of multi- and extensively drug-resistant gonorrhoea in Europe: 2019 update. 2019. Accessed February 10, 2023. (Technical report)
  110. Krupp K, Madhivanan P. Antibiotic resistance in prevalent bacterial and protozoan sexually transmitted infections. Indian J Sex Transm Dis AIDS. 2015;36(1):3-8. (Review) DOI: 10.4103/0253-7184.156680
  111. Roche. ROCEPHIN® (ceftriaxone sodium) for injection. 2004. Accessed February 10, 2023. (Drug company package insert)
  112. Schillinger JA, Gorwitz R, Rietmeijer C, et al. The expedited partner therapy continuum: a conceptual framework to guide programmatic efforts to increase partner treatment. Sex Transm Dis. 2016;43(2 Suppl 1):S63-S75. (Systematic review; 42 articles) DOI: 10.1097/OLQ.0000000000000399
  113. Shiely F, Hayes K, Thomas KK, et al. Expedited partner therapy: a robust intervention. Sex Transm Dis. 2010;37(10):602-607. (Randomized controlled trial; 1860 patients)
  114. Expedited partner therapy. Centers for Disease Control and Prevention. Last reviewed April 19, 2021. Accessed February 10, 2023. (CDC website)
  115. Mehta SD. Systematic review of randomized trials of treatment of male sexual partners for improved bacteria vaginosis outcomes in women. Sex Transm Dis. 2012;39(10):822-830. (Systematic review of 8 randomized controlled trials)
  116. Kissinger P, Schmidt N, Mohammed H, et al. Patient-delivered partner treatment for Trichomonas vaginalis infection: a randomized controlled trial. Sex Transm Dis. 2006;33(7):445-450. (Randomized controlled trial; 463 patients)
  117. About Zika. Centers for Disease Control and Prevention. Last reviewed May 20, 2019. Accessed February 10, 2023. (Overview)
  118. Monkeypox: past U.S. cases and outbreaks. Centers for Disease Control and Prevention. Last reviewed June 6, 2022. Accessed February 10, 2023. (CDC information)
  119. CDC Health Alert Network. Updated case-finding guidance: monkeypox outbreak—United States, 2022. Centers for Disease Control and Prevention. Last reviewed June 14, 2022. Accessed February 10, 2023. (CDC public health update)
  120. 2022 national notifiable infectious diseases (historical). Centers for Disease Control and Prevention. Accessed February 10, 2023. (CDC website)
  121. Hosenfeld CB, Workowski KA, Berman S, et al. Repeat infection with Chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis. 2009;36(8):478-489. (Systematic review; 47 studies)
  122. Owens DK, Davidson KW, Krist AH, et al. Screening for HIV infection: US Preventive Services Task Force recommendation statement. JAMA. 2019;321(23):2326-2336.(Practice recommendation) DOI: 10.1001/jama.2019.6587
  123. Carter MW, Wu H, Cohen S, et al. Linkage and referral to HIV and other medical and social services: a focused literature review for sexually transmitted disease prevention and control programs. Sex Transm Dis. 2016;43(2 Suppl 1):S76-S82. (Systematic review; 33 studies) DOI: 10.1097/OLQ.0000000000000290
  124. Burns CM, Endres K, Farrow L, et al. Perceptions on HIV pre-exposure prophylaxis among urgent care clinicians in the southern United States. Curr HIV Res. 2022. (Cross-sectional survey; 82 urgent care clinicians) DOI: 10.2174/1570162X20666220426094920
  125. Menchine M, Zhou M, Lotfipour S, et al. Moving beyond screening: how emergency departments can help extinguish the HIV/AIDS epidemic. West J Emerg Med. 2016;17(2):135-138. (Review)
  126.  Human immunodeficiency virus (HIV) infection: screening. US Preventive Services Task Force. July 11, 2019. Accessed February 10, 2023. (Recommendation statement)
  127. Hess KL, Javanbakht M, Brown JM, et al. Intimate partner violence and sexually transmitted infections among young adult women. Sex Transm Dis. 2012;39(5):366-371.(Retrospective study; 3548 patients)

Genital or anal ulcers, chancre, or warts
Genital or anal ulcers, chancre, or warts
Skin rash, neurologic changes, lymphadenopathy
Skin rash, neurologic changes, lymphadenopathy
Vaginal Discharge
Vaginal Discharge
Urethritis, Cervicitis
Urethritis, Cervicitis
FacebookTwitterLinkedInInstagramYouTubePinterest

EB Medicine

FOAMed

Podcast

© EB Medicine. All rights reserved